The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy and safety of nivolumab (Nivo) in patients (pts) with advanced or recurrent uterine cervical or corpus cancers.
 
Kosei Hasegawa
Honoraria - Chugai Pharma; Daiichi Sankyo; Ono Pharmaceutical
Consulting or Advisory Role - Daiichi Sankyo; MSD
Research Funding - OncoTherapy Science; Pfizer; Yakult Pharmaceutical
 
Kenji Tamura
No Relationships to Disclose
 
Noriyuki Katsumata
Honoraria - Ono Pharmaceutical
 
Koji Matsumoto
Honoraria - AstraZeneca; Chugai Pharma; Eisai; Kyowa Hakko Kirin; Nihonkayaku; Novartis; Ono Pharmaceutical
Research Funding - AstraZeneca; MSD; Novartis; Ono Pharmaceutical
 
Shunji Takahashi
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Eisai; MSD; Novartis; Sanofi; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Daiichi Sankyo; Novartis
 
Hirofumi Mukai
Honoraria - AstraZeneca; Chugai Pharma; Pfizer; Taiho Pharmaceutical
Research Funding - Lilly (Inst); Merck (Inst); Ono Pharmaceutical (Inst)
 
Hiroyuki Nomura
No Relationships to Disclose
 
Hironobu Minami
Honoraria - Bayer; Bristol-Myers Squibb Japan; Celgene; Chugai Pharma; Daiichi Sankyo; Dainippon Sumitomo Pharma; Eisai; Janssen; Kowa; Kyowa Hakko Kirin; Lilly Japan; Merck Serono; Novartis; Ono Pharmaceutical; Otsuka; Pfizer; Sanofi; Sanofi; Shire; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Merck Serono; Ono Pharmaceutical
Research Funding - Astellas Pharma (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst)